Discover why Viking Therapeutics, Inc.'s VK2735 could lead GLP-1 obesity drugs. Click for my updated look at VKTX stock ...
Viking Therapeutics CEO Brian Lian is watching the growth of interest in MASH and obesity but prepared to go it alone.
Viking Therapeutics (($VKTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Viking Therapeutics’ recent earnings ...
Zacks Investment Research on MSN
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
Viking Therapeutics VKTX reported a third-quarter 2025 loss of 81 cents per share, wider than the Zacks Consensus Estimate of ...
Viking is developing VK2735, its dual GIP/GLP-1 receptor agonist, in injectable form -- like current marketed weight ...
Viking Therapeutics focuses on metabolic therapies with a strong pipeline, takeover potential, and late-stage obesity drug ...
Despite a significant increase in net loss, Viking Therapeutics Inc (VKTX) progresses with promising clinical trials and ...
Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated SAN DIEGO, Oct. 21, 2025 /PRNewswire/ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback